Assuming a Master Services Agreement with a top 10 Global23 May 2026 12:54
Pharma co. is signed, as expected, the next question will be what work will the aggreement create?
My opinion is ALL CANCER DRUG trials that involve participants with cancer that is at a stage where it might spread, or is known to be spreading should have the circulating tumor cells analysed. How many are found from each sample indicates if the spread is increasing or decreasing. Also testing PD-L1 can show if the person is suitable for other treatments (if necessary). Then of course one would have thought the pharma Co.would want to know exactly how the drug is affecting the CTC's, after all they are the cancer. This must be valuable information for the future.
Frankly I am astonished and bewildered this does not happen already. This could have been general practce for a couple of YEARS by now.
All IMHO.